Home > Insider Trading > Filing (0001562180-20-005109)

Filing Details

Accession Number:: 0001562180-20-005109
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-13 16:02:56
Reporting Period:: 2020-07-09

Accepted Time:: 2020-07-13 16:02:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
842023	Bio-Techne Corp	TECH	Biological Products, (No Disgnostic Substances) (2836)	411427402

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1443851	S. Brenda Furlow	614 Mckinley Place Ne Minneapolis MN 55413	Svp - General Counsel	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-07-09	9,079	$108.49	13,390	No	4	M	Direct
Common Stock	Disposition	2020-07-09	440	$270.97	12,950	No	4	S	Direct
Common Stock	Disposition	2020-07-09	505	$272.48	12,445	No	4	S	Direct
Common Stock	Disposition	2020-07-09	2,042	$273.33	10,403	No	4	S	Direct
Common Stock	Disposition	2020-07-09	918	$274.80	9,485	No	4	S	Direct
Common Stock	Disposition	2020-07-09	400	$276.03	9,085	No	4	S	Direct
Common Stock	Disposition	2020-07-09	1,954	$277.28	7,131	No	4	S	Direct
Common Stock	Disposition	2020-07-09	2,746	$278.06	4,385	No	4	S	Direct
Common Stock	Disposition	2020-07-09	74	$278.84	4,311	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-07-09	9,079	$0.00	9,079	$108.49

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
921		2022-08-07	No	4	M	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Restricted Stock Units	$0.00		1,724	1,724	Direct
Common Stock	Restricted Stock Units	$0.00		1,969	1,969	Direct
Common Stock	Restricted Stock Units	$0.00		1,374	1,374	Direct
Common Stock	Stock Option (Right to Buy)	$106.59	2023-08-18	10,857	10,857	Direct
Common Stock	Stock Options (Right to Buy)	$190.41	2026-08-07	13,290	13,290	Direct
Common Stock	Stock Options (Right to Buy)	$177.32	2025-08-08	9,786	9,786	Direct
Common Stock	Stock Options (Right to buy)	$177.32	2025-08-08	7,339	7,339	Direct
Common Stock	Stock Options (Right to Buy)	$125.05	2024-08-09	12,670	12,670	Direct
Common Stock	Stock Options (Right to buy)	$125.05	2024-08-09	9,503	9,503	Direct
Common Stock	Stock Options (Right to Buy)	$106.59	2023-08-18	14,476	14,476	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
	1,724	1,724	Direct
	1,969	1,969	Direct
	1,374	1,374	Direct
2023-08-18	10,857	10,857	Direct
2026-08-07	13,290	13,290	Direct
2025-08-08	9,786	9,786	Direct
2025-08-08	7,339	7,339	Direct
2024-08-09	12,670	12,670	Direct
2024-08-09	9,503	9,503	Direct
2023-08-18	14,476	14,476	Direct

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.6400 to $271.5000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.8500 to $272.8300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.8500 to $273.7900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.3100 to $275.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.4000 to $276.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.6500 to $277.6200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.7700 to $278.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Vests 2,500 share(s) on 07-Aug-2016, 2,500 share(s) on 07-Aug-2017, 2,500 share(s) on 07-Aug-2018, 1,579 share(s) on 07-Aug-2019
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)
Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Fully exercisable
Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.
Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.
Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021.
Options to purchase 3,619 shares vest on each of 8/18/2017, 8/18/2018, 8/18/2019 and 8/18/2020.